scispace - formally typeset
Search or ask a question

Showing papers on "Benzopyran published in 2001"


Journal ArticleDOI
TL;DR: In this paper, a simple efficient and environment ecofriendly route has been developed for the synthesis of ylidenenitriles of======4-oxo-(4H)-1-benzopyran-3-carbaldehyde by the condensation of======ργαβδαβαββα βαβγα ββββγ βαγβαγ ββγβγγ βγαγγαα βγββ βγγ αβγδβααβ ββα αβ

44 citations


Journal ArticleDOI
TL;DR: The title aldehyde 1 in the presence of ammonia gives the pyridine derivatives 9-11 respectively with acetylacetone, diethyl malonate and ethyl cyanoacetate, and the coumarinopyridines 25 and 26, respectively as discussed by the authors.

39 citations


Journal ArticleDOI
TL;DR: In this article, a 2.5-Methoxy-2,2-dimethyl-2H-1-benzopyran-6-propanoic acid methyl ester was prepared in five steps and approximately 20% overall yield from 2,4-dihydroxybenzaldehyde.

27 citations


Journal ArticleDOI
TL;DR: From the leaves of Mallotus apelta, seven benzopyran compounds were obtained and their structures were determined using spectroscopic methods and one showed moderate antibiotic activity against Micrococcus lutens.

24 citations


Journal ArticleDOI
TL;DR: Among the substituents at 4' position examined, the most favourable for inhibitory activity are those able to act as hydrogen bond donors, supporting the hypothesis of the importance of the interaction with Thr113 for the inhibition of the enzyme.

20 citations


Journal ArticleDOI
TL;DR: In this paper, the synthesis of bisbenzopyran-4-ol (1) was performed through the key steps of iodination, nickel modified Ullmann-type reaction, hydrogen-transfer hydrogenation and diastereoselective reduction.

14 citations


Journal ArticleDOI
TL;DR: In this article, both types of polycyclic compound and their analogous 4H-thieno derivatives were functionalized at C-2 by aromatic electrophilic substitution (bromination, nitration, acetylation and formylation).
Abstract: 4,4-dialkyl-1H-[1]benzopyrano[4,3-b]pyrroles were prepared starting from [1]benzopyrano[4,3-b]pyrrol-4(1H)-ones and organometallic reagents. Subsequently, both types of polycyclic compound and their analogous 4H-thieno[3,2-c][1]benzopyrano derivatives were functionalized at C-2 by aromatic electrophilic substitution (bromination, nitration, acetylation and formylation).

9 citations



Journal ArticleDOI
TL;DR: In this article, the chemical shift assignments were based on two-dimensional experiments for seven 2-oxo-2H-1-benzopyran-3-carboxamide derivatives.
Abstract: 1H and 13C NMR spectral data for seven 2-oxo-2H-1-benzopyran-3-carboxamide and two 2-oxo-2H-1-benzopyran-3-amide derivatives are reported. The chemical shift assignments were based on two-dimensional experiments. Copyright © 2001 John Wiley & Sons, Ltd.

7 citations


Journal ArticleDOI
TL;DR: In this paper, the formation of methylene-bis derivatives of benzopyran-4-ones from their Mannich bases was studied, and unsymmetrical methylene derivatives were synthesized by reacting Mannich base of BN with structurally related compounds lacking the dialkylaminomethyl group.

6 citations


Patent
17 Oct 2001
TL;DR: In this article, a photochromatic benzopyran compound, its preparation process and the photo chromatic products containing it are described. And the present invention relates to the photochromic benzopryran compounds, its preparing process and its contents.
Abstract: The present invention relates to a photochromatic benzopyran compound, its preparing process and the photochromatic products containing it. Said photochromatic compound has high comprehensive performance and better anti-fatigue nature.


Patent
16 Jan 2001
TL;DR: In this paper, the problem of obtaining a new compound useful for a red-based fluorescent coloring matter having high excellent characteristics such as emission brightness, fastness and excellent luminous efficiency suitable in the field of an organic electric field light emission element was solved.
Abstract: PROBLEM TO BE SOLVED: To obtain a new compound useful for a red-based fluorescent coloring matter having high excellent characteristics such as emission brightness, fastness and excellent luminous efficiency suitable in the field of an organic electric field light emission element. SOLUTION: This compound is shown by formula [R1 to R4 are each H or a 1-4C alkyl; ring Z is a (substitute) aromatic ring] such as a compound of formula II. The compound of formula I is obtained by reacting a compound of formula III (e.g. 1,1,7,7-tetramethyl-8-hydroxy-9-formyljulolidine, etc.), with a compound of formula IV (e.g. 2-benzimidazolylacetonitrile, etc.), generally in an inert solvent such as N,N-dimethylformamide, etc., in the presence of an inorganic or an organic basic condensation agent preferably at 0-50 deg.C for about 0.5-48 hours to synthesize a compound of formula V, then reacting the compound with malononitrile preferably at 50-200 deg.C for 0.5-48 hours and hydrolyzing the formed compound.

Patent
04 Jun 2001
TL;DR: In this paper, a novel polymorphic form of anhydrous crystalline (3S- trans )-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2 H -1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoicacid, hereinafter compound (I), and a novel salt, and a hydrate of said compound, are described, where each novel composition has particular characteristics that contribute to its use in pharmaceutical formulations.
Abstract: The present invention provides novel polymorphic forms of anhydrous crystalline (3S- trans )-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2 H -1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid, hereinafter compound (I), and a novel salt, and a hydrate of said compound, wherein each novel composition has particular characteristics that contribute to its use in pharmaceutical formulations. The novel monohydrate of compound (I) is described, which can be advantageously isolated from water wet solvents and formulated via wet granulation techniques. The novel ethylene diamine (mono) salt is also described, and demonstrates superior solubility and bioavailability. Additionally, polymorphic forms A and B of anhydrous crystalline compound (I) are described, wherein form A has superior thermal stability, and form B has superior solubility. Additionally, there are described pharmaceutical compositions that comprise these substances, and methods for the treatment of disease states therewith, in particular, the treatment of inflammatory diseases.


Journal ArticleDOI
TL;DR: In the title salt, C5H12N+*C29H23O6-, both benzopyran systems are planar and intermolecular N-O hydrogen bonds and a short O--H...O intramolecular hydrogen bond are observed in the structure.
Abstract: In the title salt, C 5 H 12 N + .C 29 H 23 O 6 - , both benzopyran systems are planar. Intermolecular N-H...O hydrogen bonds and a short O-H...O intramolecular hydrogen bond are observed in the structure.

Journal Article
TL;DR: SBI β CD was synthesized for the first time and measured with UV and circular dichroism(CD) for its photochromism and complexation with (-) borneol.


Patent
01 Jun 2001
TL;DR: In this article, processes for resolving chiral (2S and (2R) benzopyrans, racemizing (1R) and recycling (2C) racemized benzoprinear agents to increase yield of a desired enantiomer to provide purified or substantially purified bicyclic amino substituted benzopyan derivatives are discussed.
Abstract: Disclosed are processes for resolving chiral (2S) and (2R) benzopyrans, racemizing benzopyrans, and recycling racemized benzopyrans to increase yield of a desired enantiomer to provide purified or substantially purified bicyclic amino substituted benzopyran derivatives. Such benzopyran derivatives are preferably chromans which can be coupled with benzoyl derivatives via an amide bond to produce potent platelet aggregation inhibitors.

Journal ArticleDOI
TL;DR: In this paper, the synthesis and characterisation of new furoisoflavones prepared from 4, 6-diacetylresorcinol was reported, and they were used in the development of a new drug.

Journal ArticleDOI
Abstract: Synthesis 2001, No. 6, 04 05 2001. Article Identifier: 1437-210X,E;2001,0,06,0924,0928,ftx,en;Z11200SS.pdf. © Georg Thieme Verlag Stuttgart · New York ISSN 0039-7881 Abstract: A number of 4-(4-aryloxybut-2-ynyloxy)[1]benzopyran2-ones 6a-h were converted to corresponding thiones 4a-h. The thiones 4a-h in refluxing 1,2-dichlorobenzene gave 4-aryloxymethylthiopyrano[2,3-b][1]benzopyran-5(2H)-ones 5a-d and products 7a-d in 20-26% and 50-55% yield, respectively, whereas thiones 4e-h furnished exclusively products 7e-h in 80-85% yield. Addition of radical initiator azobisisobutyronitrile or radical scavenger hydroquinone or acid or base does not seem to have any effect on the rearrangement. All the butynyl ethers studied so far underwent sigmatropic rearrangements at the 4-coumarin-4-yloxypropynyl function of compounds 4a-h to give products 5a-d and or 7a-h.

Journal Article
TL;DR: The structural formula of the new compounds were established by using different instrumental analyses and some compounds in this study were biologically evaluated for their ability to bind to DNA.
Abstract: Vilsmeier-Haack reaction of imidazolyl acetophenone I gave 6-imidazolyl-4-oxo-4H-1-benzopyran-3-carboxaldehyde II. The compound II was reacted with primary amines (1:1 molar ratio) to form the corresponding n-aril (meteroaryl) imino derivatives IIIa-f. Treatment of aldehyde II with excess amines (1:2 molar ratio) gave the corresponding 2-arylamino-3-arylaminomethylenebenzopyran derivatives IVa-c. The n-aril (meteroaryl) imino derivatives IIIb,d,e,f were reacted with thioglycollic acid to give benzopyranothiazepinone derivatives VIa-d. When the aldehyde II was treated with secondary amines gave the corresponding trans-enaminoketones VIIIa-c. Trans-enaminoketones VIIIa-c were reacted with hydrazines and/or hydroxylamine hydrochloride to give pyrazolyl and/or isoxazolyl benzene IXa-c and X, respectively. The reaction of aldehyde II with hydrazines on cold gave the corresponding hydrazones XIIIa-d. However, the reaction of aldehyde II with hydrazines on refluxing gave the corresponding pyrazole derivatives 5 XIVa,b and XVa,b.. The structural formula of the new compounds were established by using different instrumental analyses. Some compounds in this study were biologically evaluated for their ability to bind to DNA.


Patent
15 May 2001
TL;DR: In this paper, the authors proposed a method to obtain a labeled compound relatively easy to synthesize, and suitable for elucidating the in vivo kinetics, mechanism of various physiological activities, etc, of a flavan-3-ol compound.
Abstract: PROBLEM TO BE SOLVED: To obtain a labeled compound relatively easy to synthesize, and suitable for elucidating the in vivo kinetics, mechanism of various physiological activities, etc, of a flavan-3-ol compound partly because an isotope used as a label is hard to be eliminable SOLUTION: This compound is a flavan-3-ol compound labeled with deuterium or tritium on the 4-position and shown by the general formula (1) (wherein, R1 is H or an acyl; R2 is deuterium or tritium; R3 to R7 are each H or OH; and the steric configurations of the 2- and 3-positions of the benzopyran ring may be R- or S-configuration, respectively)


Patent
01 Jun 2001
TL;DR: In this article, processes for coupling amino substituted 2-chromanyl derivatives and benzoyl derivatives via an amide bond, and intermediates for producing platelet aggregation inhibitors were discussed.
Abstract: Disclosed are processes for coupling amino substituted 2-chromanyl derivatives and benzoyl derivatives via an amide bond, and intermediates for producing platelet aggregation inhibitors and for producing potent platelet aggregation inhibitors. Also disclosed are processes for producing such compounds from chiral intermediates to provide desired enantiomers, and methods for using the compounds as platelet aggregation inhibitors.

Patent
01 Jun 2001
TL;DR: In this article, processes for producing benzopyran compounds, reduced 2-(chroman-2-yl) acetic acid compounds and 2-(6-aminochroman 2-yl)-acetic acid esters which are intermediates for producing platelet aggregation inhibitors were described.
Abstract: Disclosed are processes for producing benzopyran compounds, reduced 2-(chroman-2-yl) acetic acid compounds and 2-(6-aminochroman-2-yl)acetic acid esters which are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors.

Patent
14 Nov 2001
TL;DR: The present paper relates to benzopyran and benzoxepine derivatives of the general formula I, wherein X represents an oxygen atom, which can be used in the prevention or treatment of dyslipidemia, atherosclerosis and diabetes as mentioned in this paper.
Abstract: The present invention relates to benzopyran and benzoxepine derivatives of the general formula I, wherein X represents an oxygen atom, which can be used in the prevention or treatment of dyslipidemia, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to processes and intermediates allowing the preparation of these compounds.

Proceedings ArticleDOI
22 May 2001
TL;DR: In this article, the spectral, fluorescent and lasing properties of a series of benzopyran derivatives were investigated for the purpose of making new active media for flashlamp-pumped dye lasers.
Abstract: Spectral, fluorescent and lasing properties of a series of benzopyran derivatives were investigated for the purpose of making new active media for flashlamp-pumped dye lasers. The influences of structure changes in this series of the dyes on their spectroscopic characteristics and the laser performance have been analyzed in the work. The fulfilled measurements have shown, that laser efficiency of investigated salts of the benzopyran derivatives exceeds one for their analogue-coumarin 7. Therewithal the compounds, in which molecular structure the free diethylamino group in the 7-th position of the benzopyran nucleus is fixed with two saturated six-membered heterocycles, have the greatest laser output. The results of the work allow developing recommendations for synthesis of new effective laser dyes among compounds of the investigated series.

Patent
20 Jun 2001
TL;DR: In this article, the authors defined a set of compounds of formula (I) or pharmaceutically acceptable salts thereof: [FORMULA] wherein: Y is C-R1 where R 1 is methyl, R 2 is hydrogen, R 3 is hydroxy, R 4-fluorophenyl, the R8-N-CO-R7 group being trans to the R5 group, and X is oxygen.
Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof: [FORMULA] wherein: Y is C-R1 where R1 is methyl; R2 is hydrogen; R3 and R4 are each methyl; R5 is hydroxy; R6, R8 and R9 are each hydrogen; R7 is 4-fluorophenyl; the R8-N-CO-R7 group being trans to the R5 group; and X is oxygen are useful in the treatment and/or prophylaxis of anxiety and/or mania, and/or depression and/or the effects associated with withdrawal from substances of above, and/or disorders treatable and/or preventable with anti-convulsive agents.